Modular Therapeutics is addressing one of the biggest challenges in medicine: many patients do not respond to existing treatments because their disease is driven by unique molecular changes that current drugs cannot target, often due to an insufficient understanding of the biological impact of these mutations. Our innovation is based on a newly discovered biological process called RNA dicing – a natural way in which cells cut and rewire genetic messages. We have found that this process can produce protein variants that play a key role in cancer, immune disorders, and other diseases.
Our technology combines advanced genetic analysis with machine learning models to detect these disease-causing variants in patient samples. This enables us to match patients with the most effective existing medicines or to guide the development of entirely new treatments. The modular nature of our approach means it can be quickly adapted to different diseases, potentially benefiting millions of patients worldwide.
Within the Biotech Booster program, we will refine our detection technology, focusing on abundant oncogenic mutations in endometrial cancer, validate it using patient samples, and lay the groundwork for personalized therapies. Our ultimate goal is to accelerate the path from discovery to treatment, improving patient outcomes and reducing healthcare costs.
